SCHEMBL4944715

SCHEMBL4944715

NC(=O)c1cc(S(N)(=O)=O)c(Cl)cc1N(F)Cc1ccco1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 8/20 0.56
▸ CA1 P00915 8/20 0.56
▸ CA2 P00918 8/20 0.56
▸ CA9 Q16790 8/20 0.56
▸ CA4 P22748 7/20 0.56
▸ CA6 P23280 7/20 0.56
▸ CA7 P43166 7/20 0.56
▸ CA14 Q9ULX7 7/20 0.56
▸ CA5B Q9Y2D0 7/20 0.56
▸ CA5A P35218 5/20 0.56
▸ CISD1 Q9NZ45 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HTR1A P08908 1/20 0.56
▸ HSD11B1 P28845 1/20 0.56
▸ SLC10A1 Q14973 1/20 0.56
▸ GPR35 Q9HC97 1/20 0.56
▸ ABCG2 Q9UNQ0 1/20 0.56
▸ APP P05067 6/20 0.49
▸ CA3 P07451 6/20 0.48
▸ CA13 Q8N1Q1 6/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL229073 0.77 CA12 (0.85) CA12CA1CA2CA9CA4
SCHEMBL10124068 0.76 CISD1 (0.60) CA12CA1CA2CA9CA4
SCHEMBL10108681 0.76 CISD1 (0.60) CA12CA1CA2CA9CA4
SCHEMBL14541535 0.75 CA12 (0.53) CA12CA1CA2CA9CA4
SCHEMBL14399052 0.74 CISD1 (0.58) CA12CA1CA2CA9CA4
Furosemide SCHEMBL29406913 0.72 CISD1 (1.00) CA12CA1CA2CA9CA4
Furosemide SCHEMBL428921 0.72 CISD1 (1.00) CA12CA1CA2CA9CA4
Furosemide SCHEMBL9811 0.72 CISD1 (1.00) CA12CA1CA2CA9CA4
SCHEMBL2880956 0.72 CA12 (0.83) CA12CA1CA2CA9CA4
SCHEMBL1741237 0.72 CA1 (0.52) CA12CA1CA2CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937242-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS NeuroTherapeutics Pharma, Inc. (US) 2008-07-02 — — EP disclosed
WO-2007047698-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS NEUROTHERAPEUTICS PHARMA, INC. (US) 2007-04-26 — — WO disclosed
Send feedback